Drug Profile
Adriforant - Novartis
Alternative Names: NVP-ZPL389-NX; PF-03893787; PF-3893787; ZPL-389; ZPL-3893787; ZPL-3893797; ZPL389-NXLatest Information Update: 10 Nov 2020
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Novartis; Pfizer
- Class Amines; Anti-inflammatories; Antiasthmatics; Antipsoriatics; Cyclopropanes; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Atopic dermatitis; Plaque psoriasis
Most Recent Events
- 29 Oct 2020 Novartis terminates the phase II ZESTExt trial in Atopic dermatitis (Treatment-experienced) in Belgium, Czech Republic, Estonia, France, Germany, Iceland, Finland, Canada, Japan, Netherlands, Poland, Russia, Slovakia, Taiwan, United Kingdom and USA due to lack of efficacy (PO) (NCT03948334) (EudraCT2018-000595-15)
- 21 Jul 2020 Novartis discontinues phase IIb ZEST trial in Atopic dermatitis (Treatment-experienced) in in Austria, Argentina, Belgium, Czech Republic, Estonia, France, Hungary, Russia, Taiwan, Slovakia, Poland, Germany, Japan, Canada, United Kingdom, Iceland, Finland, Netherlands, USA (PO) due to efficacy concern before July 2020
- 04 Apr 2019 Novartis initiates a phase II extension trial in Atopic dermatitis (Treatment-experienced) in Finland, Germany, United Kingdom, USA, Iceland, Slovakia, Russia, Netherlands, Poland, Japan, Canada (PO) (NCT03948334) (EudraCT2018-000595-15) after April 2019